Histochemical localization of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine oxidation in the mouse brain

[1]  P. Reiner,et al.  Topographie relations of cholinergic and noradrenergic neurons in the feline pontomesencephalic tegmentum: An immunohistochemical study , 1987, Brain Research Bulletin.

[2]  D. German,et al.  Axonal and transneuronal transport in the transmission of neurological disease: Potential role in system degenerations, including alzheimer's disease , 1987, Neuroscience.

[3]  C. Markham,et al.  Immunohistochemical localization of monoamine oxidase-B in the cat brain: Clues to understanding N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity , 1987, Experimental Neurology.

[4]  L. Pearce,et al.  Catecholamine-metabolizing enzyme activity in the nigrostriatal system. , 1987, Biochemical pharmacology.

[5]  H. Kimura,et al.  Reversible serotoninergic neurotoxicity ofN-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse striatum studied by neurochemical and immunohistochemical approaches , 1987, Brain Research.

[6]  J. Langston,et al.  Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+ , 1987, Neuroscience Letters.

[7]  T. Maeda,et al.  Distribution of two types of monoamine oxidase-containing neurons in the cat medulla oblongata demonstrated by an improved histochemical method , 1987, Neuroscience.

[8]  L. Kochersperger,et al.  Immunocytochemical localization of monoamine oxidases A and B in human peripheral tissues and brain. , 1987, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[9]  E. Pikarski,et al.  Effect of serotonergic, corticostriatal and kainic acid lesions on the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6- tetrahydropyridine (MPTP) in mice , 1986, Brain Research.

[10]  T. Maeda,et al.  Topographic atlas of monoamine oxidase-containing neurons in the rat brain studied by an improved histochemical method , 1986, Neuroscience.

[11]  T. Maeda,et al.  Demonstration of monoamine oxidase type B in serotonergic and type A in noradrenergic neurons in the cat dorsal pontine tegmentum by an improved histochemical technique , 1986, Neuroscience Letters.

[12]  H. Kinemuchi,et al.  The ex vivo effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on rat intra- and extraneuronal monoamine oxidase activity , 1986, Neuroscience Letters.

[13]  J. Luthman,et al.  Effect of MPTP and its pyridinium metabolites on monoamine uptake and on central catecholamine neurons in mice. , 1986, Acta physiologica Scandinavica.

[14]  W. Staines,et al.  Neuronal colocalization of adenosine deaminase, monoamine oxidase, galanin and 5-hydroxytryptophan uptake in the tuberomammillary nucleus of the rat , 1986, Brain Research Bulletin.

[15]  S. Vincent,et al.  Histochemistry of MPTP oxidation in the rat brain: Sites of synthesis of the parkinsonism-inducing toxin MPP+ , 1986, Neuroscience Letters.

[16]  H. Groenewegen,et al.  Histaminergic projections from the premammillary and posterior hypothalamic region to the caudate-putamen complex in the rat , 1986, Brain Research.

[17]  E. Sundström,et al.  Differential time course of protection by monoamine oxidase inhibition and uptake inhibition against MPTP neurotoxicity on central catecholamine neurons in mice. , 1986, European journal of pharmacology.

[18]  H. Takagi,et al.  Histaminergic axons in the neostriatum and cerebral cortex of the rat: a correlated light and electron microscopic immunocytochemical study using histidine decar☐ylase as a marker , 1986, Brain Research.

[19]  E. Melamed,et al.  In vivo effect of MPTP on monoamine oxidase activity in mouse striatum , 1985, Brain Research.

[20]  R. M. Rose,et al.  Distinct monoamine oxidase A and B populations in primate brain. , 1985, Science.

[21]  E. Melamed,et al.  Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP. , 1985, European journal of pharmacology.

[22]  A. Brossi,et al.  Serotonergic conversion of MPTP and dopaminergic accumulation of MPP+ , 1985, FEBS letters.

[23]  L. Pearce,et al.  Cellular localization of MAO A and B in brain: Evidence from kainic acid lesions in striatum , 1985, Brain Research.

[24]  S. Snyder,et al.  NORMAL MPTP BINDING IN PARKINSONIAN SUBSTANTIA NIGRA: EVIDENCE FOR EXTRANEURONAL TOXIN CONVERSION IN HUMAN BRAIN , 1985, The Lancet.

[25]  E. Sundström,et al.  Pharmacological interference with the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse. , 1985, European journal of pharmacology.

[26]  S. Snyder,et al.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Parsons,et al.  Localization in rat brain of binding sites for parkinsonian toxin MPTP: similarities with [3H]parygyline binding to monoamine oxidase , 1985, Brain Research.

[28]  R. Duvoisin,et al.  Effects of 1‐Methyl‐4‐Phenyl‐1,2,5,6‐Tetrahydropyridine and Related Compounds on the Uptake of [3H]3,4‐Dihydroxyphenylethylamine and [3H]5‐Hydroxytryptamine in Neostriatal Synaptosomal Preparations , 1985, Journal of neurochemistry.

[29]  R. Duvoisin,et al.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors , 1984, Nature.

[30]  R. S. Burns,et al.  Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.

[31]  J. Langston,et al.  Pargyline prevents MPTP-induced parkinsonism in primates. , 1984, Science.

[32]  G. Uhl,et al.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Duvoisin,et al.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.

[34]  S. Finklestein,et al.  Effects of N-substituted phenyltetrahydropyridines on cerebral high-affinity synaptosomal uptake of dopamine and other monoamines in several mammalian species. , 1984, Life sciences.

[35]  K. Chiba,et al.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.

[36]  L. Olson,et al.  Neurotoxicity of the meperidine analogue N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse. , 1984, European journal of pharmacology.

[37]  T. Maeda,et al.  HISTOCHEMISTRY OF THE MAGNOCELLULAR NEURONS IN THE POSTERIOR HYPOTHALAMUS, WITH SPECIAL REFERENCE TO MAO ACTIVITY AND ABILITY OF 5HTP UPTAKE AND DECARBOXYLATION , 1984 .

[38]  K. Jellinger,et al.  Dementia in Parkinson's disease and (pre) senile dementia of Alzheimer type: morphological aspects and changes in the intracerebral MAO activity. , 1984, Advances in neurology.

[39]  X. Breakefield,et al.  Specificity of antisera prepared against pure bovine MAO-B , 1983, Brain Research.

[40]  H. Hayashi,et al.  Evidence for the presence of a histaminergic neuron system in the rat brain: An immunohistochemical analysis , 1983, Neuroscience Letters.

[41]  E. Koot-Gronsveld,et al.  Localization of rat striatal monoamine oxidase activities towards dopamine, serotonin and kynuramine by gradient centrifugation and nigro-striatal lesions. , 1983, Life sciences.

[42]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[43]  T. Hökfelt,et al.  Hypothalamic gamma-aminobutyric acid neurons project to the neocortex. , 1983, Science.

[44]  D. Schoepp,et al.  Effects of Intrastriatal Kainic Acid Injection on [3H]Dopamine Metabolism in Rat Striatal Slices: Evidence for Postsynaptic Glial Cell Metabolism by Both the Type A and B Forms of Monoamine Oxidase , 1983, Journal of neurochemistry.

[45]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[46]  T. Maeda,et al.  Histochemical demonstration for monoamine oxidase (MAO) by a new coupled peroxidation method. , 1983, Cellular and molecular biology.

[47]  X. Breakefield,et al.  Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[48]  C. Milstein,et al.  Immunocytochemical detection of serotonin with monoclonal antibodies. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[49]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[50]  D. J. Smith,et al.  The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons. , 1980, The Journal of pharmacology and experimental therapeutics.

[51]  T. Hattori,et al.  Dorsal raphe cells with collateral projections to the caudate-putamen and substantia nigra: A fluorescent retrograde double labeling study in the rat , 1980, Brain Research.

[52]  A. Carlsson,et al.  Monoamine oxidase -A and -B activity in the rat brain after hemitransection. , 1980, Life sciences.

[53]  Sanford P. Markey,et al.  Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.

[54]  D. Murphy,et al.  SUBSTRATE AND INHIBITOR‐RELATED CHARACTERISTICS OF MONOAMINE OXIDASE IN C6 RAT GLIAL CELLS , 1976, Journal of Neurochemistry.

[55]  O. Hornykiewicz,et al.  The neurochemistry of Parkinson's disease: effect of L-dopa therapy. , 1975, The Journal of pharmacology and experimental therapeutics.

[56]  H. Fibiger,et al.  Anatomical and electrophysiological identification of a projection from the mesencephalic raphe to the caudate-putamen in the rat , 1975, Brain Research.

[57]  Y. Agid,et al.  Monoamine oxidase and aldehyde dehydrogenase activity in the striatum of rats after 6‐hydroxydopamine lesion of the nigrostriatal pathway , 1973, British journal of pharmacology.

[58]  T. Sourkes,et al.  Aldehyde dehydrogenase and monoamine oxidase in the striatum of cats with nigrostriatal lesions , 1972, Journal of neurochemistry.

[59]  C. Marsden,et al.  Effect of nigral and raphé lesions on the catechol-O-methyl transferase and monoamine oxidase activities in the rat striatum. , 1972, European journal of pharmacology.

[60]  K. Magyar,et al.  Some puzzling pharmacological effects of monoamine oxidase inhibitors. , 1972, Advances in biochemical psychopharmacology.

[61]  N. Uretsky,et al.  EFFECTS OF 6‐HYDROXYDOPAMINE ON CATECHOLAMINE CONTAINING NEURONES IN THE RAT BRAIN , 1970, Journal of neurochemistry.

[62]  M. Goldstein,et al.  STUDIES OF AMINES IN THE STRIATUM IN MONKEYS WITH NIGRAL LESIONS , 1969, Journal of neurochemistry.

[63]  J. P. Johnston.  Some observations upon a new inhibitor of monoamine oxidase in brain tissue. , 1968, Biochemical pharmacology.

[64]  M. Karnovsky,et al.  THE HISTOCHEMICAL DEMONSTRATION OF MONOAMINE OXIDASE ACTIVITY BY COUPLED PEROXIDATIC OXIDATION , 1965, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[65]  G. Glenner,et al.  THE HISTOCHEMICAL DEMONSTRATION OF MONOAMINE OXIDASE ACTIVITY BY TETRAZOLIUM SALTS , 1957, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.